Renaissance Technologies LLC grew its holdings in OraSure Technologies, Inc. (NASDAQ:OSUR) by 14.0% during the 2nd quarter, Holdings Channel.com reports. The fund owned 4,965,803 shares of the medical instruments supplier’s stock after acquiring an additional 610,300 shares during the period. Renaissance Technologies LLC owned 0.08% of OraSure Technologies worth $46,083,000 at the end of the most recent reporting period.
Several other institutional investors have also made changes to their positions in OSUR. Acadian Asset Management LLC bought a new position in shares of OraSure Technologies in the second quarter worth about $25,000. Roble Belko & Company Inc purchased a new position in OraSure Technologies in the 1st quarter worth approximately $29,000. Parallel Advisors LLC purchased a new position in OraSure Technologies in the 1st quarter worth approximately $33,000. Quantamental Technologies LLC bought a new position in OraSure Technologies in the 1st quarter worth approximately $56,000. Finally, Panagora Asset Management Inc. boosted its stake in OraSure Technologies by 34.3% in the 2nd quarter. Panagora Asset Management Inc. now owns 9,851 shares of the medical instruments supplier’s stock worth $91,000 after purchasing an additional 2,514 shares during the period. Institutional investors and hedge funds own 94.32% of the company’s stock.
A number of equities research analysts have issued reports on the stock. Canaccord Genuity reaffirmed a “hold” rating and set a $7.00 price objective on shares of OraSure Technologies in a report on Wednesday, August 14th. Zacks Investment Research downgraded shares of OraSure Technologies from a “hold” rating to a “sell” rating in a report on Tuesday, July 9th. Finally, BidaskClub downgraded shares of OraSure Technologies from a “sell” rating to a “strong sell” rating in a report on Wednesday, August 14th. Three investment analysts have rated the stock with a sell rating and one has assigned a hold rating to the company. The stock has an average rating of “Sell” and an average target price of $7.00.
OraSure Technologies (NASDAQ:OSUR) last issued its earnings results on Tuesday, August 6th. The medical instruments supplier reported $0.07 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.03 by $0.04. OraSure Technologies had a return on equity of 7.81% and a net margin of 11.83%. The firm had revenue of $38.83 million for the quarter, compared to analysts’ expectations of $41.48 million. During the same period in the previous year, the firm posted $0.07 earnings per share. The business’s revenue was down 11.0% compared to the same quarter last year. As a group, analysts expect that OraSure Technologies, Inc. will post 0.37 EPS for the current year.
OraSure Technologies Profile
OraSure Technologies, Inc, together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, OSUR and DNAG. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests.
Recommended Story: What is the market perform rating?
Want to see what other hedge funds are holding OSUR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for OraSure Technologies, Inc. (NASDAQ:OSUR).
Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.